1. Home
  2. ANIK vs PLX Comparison

ANIK vs PLX Comparison

Compare ANIK & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Anika Therapeutics Inc.

ANIK

Anika Therapeutics Inc.

HOLD

Current Price

$14.97

Market Cap

197.6M

Sector

Health Care

ML Signal

HOLD

Logo Protalix BioTherapeutics Inc. (DE)

PLX

Protalix BioTherapeutics Inc. (DE)

HOLD

Current Price

$1.95

Market Cap

174.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANIK
PLX
Founded
1983
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
197.6M
174.0M
IPO Year
1996
1996

Fundamental Metrics

Financial Performance
Metric
ANIK
PLX
Price
$14.97
$1.95
Analyst Decision
Buy
Strong Buy
Analyst Count
1
1
Target Price
$17.00
$12.00
AVG Volume (30 Days)
115.6K
543.9K
Earning Date
04-29-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
80.16
N/A
EPS
N/A
N/A
Revenue
$112,819,000.00
$52,744,000.00
Revenue This Year
$5.98
$36.81
Revenue Next Year
$7.42
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.90
$1.34
52 Week High
$16.24
$3.19

Technical Indicators

Market Signals
Indicator
ANIK
PLX
Relative Strength Index (RSI) 52.03 31.07
Support Level $13.81 $1.43
Resistance Level $15.74 $2.14
Average True Range (ATR) 0.93 0.07
MACD -0.16 -0.01
Stochastic Oscillator 69.44 3.77

Price Performance

Historical Comparison
ANIK
PLX

About ANIK Anika Therapeutics Inc.

Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.

About PLX Protalix BioTherapeutics Inc. (DE)

Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.

Share on Social Networks: